BRPI0606393A2 - prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo - Google Patents

prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo

Info

Publication number
BRPI0606393A2
BRPI0606393A2 BRPI0606393-4A BRPI0606393A BRPI0606393A2 BR PI0606393 A2 BRPI0606393 A2 BR PI0606393A2 BR PI0606393 A BRPI0606393 A BR PI0606393A BR PI0606393 A2 BRPI0606393 A2 BR PI0606393A2
Authority
BR
Brazil
Prior art keywords
active vitamin
vitamin
prevention
animal
compound
Prior art date
Application number
BRPI0606393-4A
Other languages
English (en)
Inventor
John G Curd
William David Henner
Tomasz M Beer
Bradford S Goodwin
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of BRPI0606393A2 publication Critical patent/BRPI0606393A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PREVENçãO DE DOENçAS TROMBóTICAS COM COMPOSTOS ATIVOS DE VITAMINA D OU SIMILARES DO MESMO. A presente invenção refere-se a um método para prevenir, tratar, ou melhorar doenças trombóticas em um animal, compreendendo administrar um composto ativo de vitamina D ou um similar do mesmo. De acordo com a invenção, o composto ativo de vitamina D ou o seu similar deve ser administrado por HDPA, de modo que altas doses do composto ativo de vitamina D ou do seu similar possam ser administradas a um animal sem induzir severa hipercalcemia sintomática. A invenção também se refere a um método para prevenir, tratar, ou melhorar doenças trombóticas em um animal, compreendendo administrar ao animal um composto ativo de vitamina D ou um similar do mesmo em combinação com um ou mais outros agentes terapêuticos.
BRPI0606393-4A 2005-01-05 2006-01-05 prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo BRPI0606393A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64113705P 2005-01-05 2005-01-05
US72113005P 2005-09-28 2005-09-28
PCT/US2006/000181 WO2006074226A2 (en) 2005-01-05 2006-01-05 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof

Publications (1)

Publication Number Publication Date
BRPI0606393A2 true BRPI0606393A2 (pt) 2009-06-23

Family

ID=36648140

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606393-4A BRPI0606393A2 (pt) 2005-01-05 2006-01-05 prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo

Country Status (9)

Country Link
US (1) US20070037779A1 (pt)
EP (1) EP1833485A2 (pt)
JP (1) JP2008526856A (pt)
AU (1) AU2006204091A1 (pt)
BR (1) BRPI0606393A2 (pt)
CA (1) CA2593982A1 (pt)
MX (1) MX2007008227A (pt)
NO (1) NO20074018L (pt)
WO (1) WO2006074226A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
AU2004265238A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin D compounds in combination with other treatments
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
WO2004110380A2 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
JP2007537263A (ja) * 2004-05-10 2007-12-20 ノバセア インコーポレイティッド 活性ビタミンｄ化合物による動脈再狭窄の予防法
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
AU2006294819A1 (en) * 2005-09-26 2007-04-05 Novacea, Inc. Prevention and treatment of gastrointestinal and bladder disorders using active vitamin D compounds
US20100209536A1 (en) * 2006-09-26 2010-08-19 The Brigham And Women's Hospital, Inc. Methods and Kits for Use in the Treatment and Prevention of Diseases or Conditions of the Immune System or Infectious Diseases
EP2129382A4 (en) * 2007-02-21 2011-01-19 Univ Michigan COMPOSITIONS AND METHODS FOR HEART MUSCLE PREVENTION
WO2011024208A1 (en) * 2009-08-24 2011-03-03 Colotech A/S Combination dosage form with acetylsalicylic acid, calcitriol and calcium
FI20135701A7 (fi) * 2013-06-26 2014-12-27 Mas Metabolic Analytical Services Oy Farmaseuttisesti käyttökelpoinen ja turvallinen kombinaatio käytettäväksi merkittävien sairauksien hoidossa
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
SG11201912887VA (en) * 2017-06-29 2020-01-30 Skyline Biosciences Llc Isotretinoin oral-mucosal formulations and methods for using same
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208964T3 (es) * 1996-12-10 2004-06-16 G.D. SEARLE & CO. Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion.
JP2002509888A (ja) * 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2007537263A (ja) * 2004-05-10 2007-12-20 ノバセア インコーポレイティッド 活性ビタミンｄ化合物による動脈再狭窄の予防法
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof

Also Published As

Publication number Publication date
EP1833485A2 (en) 2007-09-19
WO2006074226A3 (en) 2006-11-16
JP2008526856A (ja) 2008-07-24
CA2593982A1 (en) 2006-07-13
WO2006074226A2 (en) 2006-07-13
NO20074018L (no) 2007-10-02
AU2006204091A1 (en) 2006-07-13
US20070037779A1 (en) 2007-02-15
MX2007008227A (es) 2007-09-11

Similar Documents

Publication Publication Date Title
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
MX2007008227A (es) Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BR0306919A (pt) Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR112019001457A2 (pt) tratamento e prevenção de distúrbios do sono
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2008005560A8 (en) Prevention of thrombotic disorders with active vitamin d compounds
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
BR112012006010A2 (pt) composto de glicina
PL1680128T3 (pl) Heksafosforan mio-inozytolu do stosowania miejscowego
BRPI0408882A (pt) composições contendo lactulose para tratamento de infecções por rotavìrus
BR112015029468A8 (pt) sistemas de dosagem oralmente administráveis, método para suplementar a nutrição de ferro em um indivíduo humano e métodos para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido
WO2006119389A3 (en) Quinine-containing controlled-release formulations
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
WO2005117542A3 (en) Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
BR112014014805A2 (pt) processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
WO2007038428A3 (en) Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: ARQUIVAMENTO DEFINITIVO

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2267 DE 17/06/2014 POR TER SIDO INDEVIDA.